New hope in fight against rare, deadly eye cancer

NCT ID NCT03070392

Completed Disease control Sponsor: Immunocore Ltd Source: ClinicalTrials.gov ↗

Summary

This study tested a new drug called IMCgp100 for people with advanced uveal melanoma, a rare and aggressive cancer that starts in the eye. It compared the new drug to standard treatment options to see which helped patients live longer. The trial involved 378 adults who had not yet received treatment for their advanced cancer and had a specific genetic marker.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Beatson West of Scotland Cancer Centre

Glasgow, G12 0YN, United Kingdom
Byers Eye Institute, Stanford University

Palo Alto, California, 94303, United States
California Pacific Medical Center

San Francisco, California, 94115, United States
Central Adelaide Local Health Network, Royal Adelaide Hospital Cancer Center

Adelaide, South Australia, 5000, Australia
Centre Atoine Lacassagne

Nice, 6189, France
Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie

Warsaw, 02-781, Poland
Charite - Campus Benjamin Franklin

Berlin, 12200/12203, Germany
Columbia University Medical Center

New York, New York, 10032, United States
Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Dnipropetrovsk State Medical Academy

Dnipro, 49102, Ukraine
Duke University Health System

Durham, North Carolina, 27710, United States
Federal State Budget Institution National Medical Research Center of Oncology

Saint Petersburg, 197758, Russia
Federal State Budgetary Institution N.N. Blokhin National Medical Research Center of Oncology

Moscow, 115478, Russia
Fondazione ICCRS

Milan, 20133, Italy
Hospital Clínico Universitario de Santiago de Compostela

Santiago de Compostela, ES-Spain, 15706, Spain
Hospital Universitario General de Valencia

Valencia, ES-Spain, 46014, Spain
Hospital Universitario La Paz

Madrid, ES-Spain, 28046, Spain
Hospital Universitario Virgen Macarena

Seville, 41009, Spain
Houston Methodist Cancer Center

Houston, Texas, 77030, United States
Institut Catala d'Oncologia (ICO) - L'Hospitalet

L'Hospitalet de Llobregat, ES-Spain, 08908, Spain
Institut Curie

Paris, 75005, France
Institut Roi Albert II Cliniques Universitaires St-Luc

Brussels, Belgium
Istituto Nazionale Tumori - IRCCS Fondazione "G. Pascale" - UOC Melanoma, Immunoterapia Oncologica e Terapie Innovative

Naples, 80131, Italy
Klinik und Poliklinik für Dermatologie und Allergologie

Munich, 80337, Germany
Kyiv Munitipal Hospital

Kyiv, 02094, Ukraine
LUMC Medical Oncology

Leiden, 2333, Netherlands
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Mount Vernon Cancer Centre

Northwood, Middlesex, HA6 2RN, United Kingdom
Nationales Centrum für Tumorerkrankungen

Heidelberg, 69120, Germany
Northwestern University

Chicago, Illinois, 60611, United States
Peter MacCallum Cancer Center

Melbourne, Victoria, 3000, Australia
Portland Providence Medical Center

Portland, Oregon, 97213, United States
Princess Margaret Cancer Centre

Toronto, M5G 2M9, Canada
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
Saint Vincents Hospital

Darlinghurst, New South Wales, 2010, Australia
The Angeles Clinic and Research Institute

Los Angeles, California, 90025, United States
The Clatterbridge Cancer Centre

Bebington, Wirral, CH63 4JY, United Kingdom
The Ohio State University

Columbus, Ohio, 43210, United States
The University of Chicago Medicine

Chicago, Illinois, 60637, United States
Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States
UCLA Medical Center

Los Angeles, California, 90024, United States
Universitaetsklinikum Koeln Dermatologie und Venerologie

Cologne, North Rhine-Westphalia, 50937, Germany
Universite Catholique de Louvain Centre du Cancer, Medical Oncology

Brussels, Belgium
University Hospital Essen

Essen, Germany
University of Colorado

Aurora, Colorado, 80045, United States
University of Hamburg

Hamburg, 20246, Germany
University of Iowa

Iowa City, Iowa, 52242, United States
University of Miami - Sylvester Comprehensive Cancer Center

Miami, Florida, 33136, United States
University of Oklahoma

Oklahoma City, Oklahoma, 73104, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15232, United States
University of Zurich Hospital

Zurich, 8091, Switzerland
Universitätsklinikum Carl Gustav Carus

Dresden, 01307, Germany
Uzhhorod Central City Clinical Hospital

Uzhhorod, 8800, Ukraine
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States

Conditions

Explore the condition pages connected to this study.

UVEAL MELANOMA